Guía de Práctica Clínica sobre Cuidados Paliativos - Cedepap TV

275. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: ameta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26(8):943-8.276. Kaplan M, Chopra S. Pruritus associated with cholestasis. In: UpToDate RB, editor. UpTo-Date.Waltham,MA: UpToDate; 2007.277. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, et al.Itch: scratching more than the surface. QJM. 2003;96(1):7-26.278. Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe nondermatologicalpruritus: a randomized, controlled trial. J Pain Symptom Manage.2003;26(6):1105-12.279. Zylicz Z, Stork N, Krajnik M. Severe pruritus of cholestasis in disseminated cancer: developinga rational treatment strategy. A case report. J Pain Symptom Manage. 2005;29(1):100-3.280. Watson MS, Lucas C.F, Hoy AM, Back IN. Skin problems in palliative care. Oxford Handbookof Palliative Care. New York: Oxford University press; 2005.281. Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J PainSymptom Manage. 2003;25(3):288-91.282. Norman R, Bailly G. Genito-urinay problems in palliative medicine. In: Doyle D, Hanks G,Chreney N, Calman K, editors. Oxford Textbook of Palliative Medicine. Third ed. Oxford:Oxford University Press; 2004.283. Agus Z.S, Berenson J.R. Treatment of hypercalcemia. In: UpToDate RB, editor. UpToDate.Waltham,MA: UpToDate; 2007.284. Bower M, Cox S. Endocrine and metabolic complications of advanced cancer. In: Doyle D,Hanks G, Chreney N, Calman K, editors. Oxford Textbook of Palliative Medicine. Third ed.Oxford: Oxford University Press; 2004.285. Saunders Y, Ross JR, Broadley KE, Edmonds PM, Patel S. Systematic review of bisphosphonatesfor hypercalcaemia of malignancy. Palliat Med. 2004;18(5):418-31.286. GPT 1. Guía de Prescripción Terapéutica. Información de medicamentos autorizados enEspaña. Adaptación española del BNF (British National Formulary). Barcelona: AgenciaEspañola de Medicamento y Productos SanitariosPharma Editores,S.L.; 2006.287. Watson MS, Lucas C.F, Hoy AM, Back IN. Emergencies in palliative care. Oxford Handbookof Palliative Care. New York: Oxford University press; 2005.288. Schiff D. Treatment and prognosis of epidural spinal cord compressión, incluiding caudaequina syndrome. In: UpToDate RB, editor. UpToDate.Waltham,MA: UpToDate; 2007.289. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis andmanagement of malignant extradural spinal cord compression: the Cancer Care OntarioPractice Guidelines Initiative’s Neuro-Oncology Disease Site Group. J Clin Oncol.2005;23(9):2028-37.290. Talcott JA, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, et al. Assessingsuspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes.Support Care Cancer. 1999;7(1):31-8.291. Klimo P, Jr., Thompson CJ, Kestle JRW, Schmidt MH. A meta-analysis of surgery versusconventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro-oncol.2005;7(1):64-76.GUÍA DE PRÁCTICA CLÍNICA SOBRE CUIDADOS PALIATIVOS 303